Katarina Miljević/LinkedIn
Jul 15, 2026, 13:43
Katarina Miljević: New Insights into Recombinant tPA and FXI Inhibition at ISTH 2026
Katarina Miljević, Postdoctoral Research Scientist at the Department of Clinical Pharmacology, Medical University of Vienna, shared a post on LinkedIn:
“I was delighted to present two posters at the ISTH 2026 Congress in Paris, highlighting research from the Department of Clinical Pharmacology MedUni Vienna, focusing on:
- Pharmacokinetic and pharmacodynamic equivalence of recombinant tPA products
- FXI inhibition with cenvacibart and its effects on hemodialysis circuit clotting
Grateful to all collaborators and co-authors who contributed to these projects.
Looking forward to the discussions and future research opportunities.”
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026
-
Oct 17, 2026, 02:32Mohammed Al Sharif: Discussing Factor XIII Testing and Its Clinical Significance
-
Oct 17, 2026, 02:31Joanna Popiolek-Kalisz: Talking about Novel Pharmacotherapy for Hypertension at CV Prevention and Intervention